Exclusive Summary

• - Core patents have largely expired; the 3.75 mg monthly depot is a global standard SKU suited for rapid entry via distribution.
• - Addresses large, durable demand in prostate cancer ADT and additional use in endometriosis/fibroids (pre-op) and CPP.
• - As a guideline-endorsed GnRH agonist and WHO EML-listed class, it enjoys strong hospital and payer acceptance.
• - JP/BP/EP-compliant API supports multi-country registration and tenders; differentiation is in reliable supply and value pricing, not redevelopment.
• - Versus originators (Lupron Depot/Procren/Enantone), typical savings of ~40–70% enable fast uptake in most markets.